News & Updates
Filter by Specialty:
Guselkumab safe, well tolerated in patients with psoriatic arthritis
Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.
Guselkumab safe, well tolerated in patients with psoriatic arthritis
10 Dec 2021
Ixekizumab effective for difficult-to-treat psoriatic arthritis
The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021
Homocysteine tied to spinal osteoarthritis prevalence in postmenopausal women
Circulating homocysteine and C677T variant in methylenetetrahydrofolate reductase (MTHFR) appear to influence the prevalence rate and ensuing progression of spinal osteoarthritis (OA), respectively, in postmenopausal women, a study has shown.
Homocysteine tied to spinal osteoarthritis prevalence in postmenopausal women
28 Nov 2021
Guselkumab yields durable benefit in biologic-naïve PsA patients
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
22 Nov 2021
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.